FAKTOR-OPTIONSSCHEIN - VERTEX PHARMACEUTICALS | Market Closed - Boerse Frankfurt Warrants 20:42:01 26/06/2024 BST | ||
| 2.59 EUR | -0.77% |
|
| Current month | -31.02% | ||
| 1 month | -33.85% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 26/06/24 | 2.58 | -1.15% |
| 25/06/24 | 2.61 | +4.40% |
| 24/06/24 | 2.5 | -8.76% |
| 21/06/24 | 2.74 | +0.37% |
| 20/06/24 | 2.73 | -6.51% |
Real-time Boerse Frankfurt Warrants
Last update June 26, 2024 at 08:42 pm
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
Société Générale
|
| WKN | SU6UKD |
| ISIN | DE000SU6UKD1 |
| Date issued | 11/01/2024 |
| Strike | 420.9 $ |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | 10.5 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 14.9 € |
|---|---|
| Lowest since issue | 2.04 € |
| Spread | 0.06 € |
| Spread % | 2.31% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
474
USD
Average target price
465.5
USD
Spread / Average Target
-1.79%
- Stock Market
- Certificates
- Certificat
